Key result
Tinzaparin and enoxaparin were equivalently effective and safe for deep-vein thrombosis prevention after total hip replacement, with no statistical difference in bleeding.
Why the study?
Does tinzaparin provide equivalent efficacy and safety compared to enoxaparin for the prevention and treatment of deep-vein thrombosis in patients undergoing elective hip replacement?
Population
499 patients undergoing elective hip replacement
Comparison
Tinzaparin vs Enoxaparin
Design
Other
Authors
Loading...
Supports use of either tinzaparin or enoxaparin for DVT prevention after total hip replacement; confirms equivalence in this RCT.
RCT (n=499)
Does tinzaparin provide equivalent efficacy and safety compared to enoxaparin for the prevention and treatment of deep-vein thrombosis in patients undergoing elective hip replacement?
Tinzaparin and enoxaparin demonstrate equivalent efficacy and safety for the prevention and treatment of deep-vein thrombosis following total hip replacement.
André Planè (2000) conducted an RCT in Deep-Vein Thrombosis after Total Hip Replacement (n=499). Tinzaparin vs. Enoxaparin was evaluated on Efficacy and safety (including incidence of bleeding). Tinzaparin and enoxaparin were equivalently effective and safe for deep-vein thrombosis prevention after total hip replacement, with no statistical difference in bleeding.